Sonoma Pharmaceuticals, Inc. (SNOA) stock
SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.01 (-0.76%)
Close on Nov 18, 2026Market cap $3.96MP/E –Yield –
Sonoma Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Sonoma Pharmaceuticals's pe ratio was 2.9× on Jan 31, 2018, against 8.8× a year earlier. Over the last 2 years it ranged from 1.1× to 9.9×, with a median of 3.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2018 | Jan 31, 2018 | 2.9× | −0.2 |
| 2017 | Dec 29, 2017 | 3.0× | −5.8 |
| 2015 | Apr 30, 2015 | 8.8× | +6.8 |
| 2014 | Dec 31, 2014 | 2.0× | – |
See a number that looks wrong?